The table below shows Intellia Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$67.67M
$57.88M
$36.27M
$52.12M
$33.05M
$57.99M
Cost of revenue
-
-
-
-
$0.00
$0.00
Gross profit
-
-
-
-
-
-
R&D
$388.86M
$466.31M
$435.07M
$419.98M
$229.81M
$150.41M
SG&A
NTLA annual revenue (10-K history)
Intellia Therapeutics, Inc. reported annual revenue of $67.67M for fiscal year 2025. That is up 16.9% from $57.88M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $16.48M (FY 2016) to $67.67M. Figures come from the company's audited annual reports as filed with the SEC.
